| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $1.94B | -39.9% |
| Cost of Revenue | $868.0M | -40.7% |
| R&D Expense | $3.13B | -31.1% |
| SG&A Expense | $1.02B | -13.3% |
| Operating Income | -$3.07B | +22.1% |
| Pre-tax Income | -$2.77B | +23.3% |
| Income Tax | $54.0M | +217.4% |
| Net Income | -$2.82B | +20.8% |
| EPS (Basic) | -$7.26 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $2.60B | +34.7% |
| Accounts Receivable | $184.0M | -48.6% |
| Inventory | $153.0M | +30.8% |
| Current Assets | $6.54B | -19.2% |
| Total Assets | $12.34B | -12.8% |
| Current Liabilities | $1.99B | -9.9% |
| Long-term Debt | $590.0M | — |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$1.87B | +37.6% |
| Capital Expenditures | $192.0M | -81.7% |
| Investing Cash Flow | $1.95B | -0.2% |
| Financing Cash Flow | $593.0M | +958.9% |
| Free Cash Flow | -$2.06B | +49.1% |
| +21.8% |
| EPS (Diluted) | -$7.26 | +21.8% |
| Total Liabilities |
| $3.69B |
| +13.8% |
| Stockholders' Equity | $8.65B | -20.6% |